amsacrine has been researched along with asulacrine in 53 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 27 (50.94) | 18.7374 |
1990's | 11 (20.75) | 18.2507 |
2000's | 5 (9.43) | 29.6817 |
2010's | 10 (18.87) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Atwell, GJ; Baguley, BC; Denny, WA; Rewcastle, GW | 1 |
Atwell, GJ; Baguley, BC; Denny, WA; Finlay, GJ; Rewcastle, GW | 1 |
Atwell, GJ; Baguley, BC; Denny, WA | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Albuquerque, APB; Almeida, SMV; Carvalho Junior, LB; Castro, MCAB; da Silva, AC; de Oliveira, JF; Lima, MDCA; Moura, RO; Nogueira, MCBL; Pereira, VRA; Ribeiro, AG; Santos, KLD; Souza, TRCL | 1 |
Anderson, RF; Kettle, AJ; Palmer, BD; Patel, KB; Robertson, IG; Winterbourn, CC | 1 |
Palmer, BD; Paxton, JW; Robertson, IG; Shaw, GJ | 1 |
Benson, L; Doroshow, JH; Grove, WR; Maroun, JA; Mittelman, A; Robert, F; Rosen, PJ; Sklarin, NT; Stewart, JA; Wiernik, PH | 1 |
Cornford, EM; Paxton, JW; Young, D | 1 |
Anderson, JA; Brown, SL; Henck, JW | 1 |
Baguley, BC; Grove, W; Hardy, JR; Harvey, VJ; Smith, S | 1 |
Baguley, BC; Finlay, GJ | 2 |
Kimmel, M; Traganos, F | 1 |
Baguley, BC; Ching, LM; Finlay, GJ; Joseph, WR | 1 |
Baguley, BC; Evans, PC; Jurlina, JL; Kestell, P; Paxton, JW; Robertson, IG; Young, D | 1 |
Kim, SN; Paxton, JW; Whitfield, LR | 1 |
Bueti, C; Darzynkiewicz, Z; Melamed, MR; Traganos, F | 1 |
Baguley, BC; Finlay, GJ; Wilson, WR | 3 |
Evans, PC; Hardy, JR; Paxton, JW | 1 |
Clark, GM; Elslager, EE; Lathan, B; Von Hoff, DD | 1 |
Baguley, BC; Ching, LM; Darkin, SJ; Lawson, PA; Ralph, RK; Schneider, E | 1 |
Paxton, JW | 1 |
Baguley, BC; Evans, P; Grillo-Lopez, AJ; Grove, W; Hardy, JR; Harvey, VJ; Paxton, JW; Smith, S | 1 |
Baguley, BC; Dormer, RA; Evans, PC; Kestell, P; Paxton, JW; Robertson, IG | 1 |
Dormer, RA; Kestell, P; Paxton, JW; Robertson, IG | 1 |
Baguley, BC; Ferguson, LR; van Zijl, P | 1 |
Baguley, BC; Calveley, SB; Harvey, VJ | 1 |
Baguley, BC; Evans, PC; Hardy, JR; Harvey, VJ; Paxton, JW | 1 |
Baguley, BC; Corbett, TH; Griswold, DP; Leopold, WR; Plowman, J | 1 |
Evans, PC; Paxton, JW; Singh, RM | 1 |
Baguley, BC; Wilson, WR | 1 |
Jurlina, JL; Paxton, JW | 2 |
DeLap, LW; Grillo-López, AJ; Grove, WR | 1 |
Frank, P; Novak, RF | 1 |
Baguley, BC; Grimwade, CD; Kernohan, AR | 1 |
Atwell, GJ; Baguley, BC; Denny, WA; Finlay, GJ; Rewcastle, GW; Twigden, SJ; Wilson, WR | 1 |
Baguley, BC; Carmichael, J; Fyfe, D; Gardner, C; Houghton, J; Langley, RE; Osborne, L; Pagonis, C; Price, C; Woll, PJ | 1 |
Carmichael, J; Clayton, K; Fyfe, D; Gardner, C; Halbert, G; Judson, I; Langley, RE; Newell, DR; Raynaud, F; Woll, PJ | 1 |
Baguley, BC; Ganta, S; Garg, S; Paxton, JW | 2 |
Baguley, BC; Liu, J; See, E; Shaw, JP; Svirskis, D; Wang, G; Wu, Z; Zhang, W | 1 |
Aa, J; Baguley, BC; Falconer, JR; Liu, J; See, E; Shaw, JP; Sun, J; Wang, G; Wu, Z; Xu, H; Zhang, W | 1 |
Amirapu, S; Baguley, BC; Liu, J; See, E; Shaw, JP; Wang, G; Wu, Z; Zhang, W | 1 |
Baguley, BC; Falconer, JR; Kanamala, M; Liu, J; Shaw, JP; Wang, G; Wu, Z; Xu, H; Zhang, W | 1 |
Afzal, A; Peng, Y; Sarfraz, M; Sheng, L; Sun, J; Wang, G; Wu, Z; Zhong, Y | 1 |
Chen, Q; Liu, J; Liu, W; Peng, Y; Sun, J; Wang, G; Zang, X; Zhang, J; Zhou, F; Zhou, Y | 1 |
Afzal, A; Sarfraz, M; Sun, J; Wang, G; Wu, Z | 1 |
Baguley, BC; Jin, Y; Li, C; Liu, J; Shaw, JP; Wu, Z; Zhang, W; Zhou, W | 1 |
Baguley, BC; Jin, Y; Li, C; Liu, J; Liu, X; Shaw, JP; Wang, Z; Wu, Z; Zhang, W | 1 |
2 review(s) available for amsacrine and asulacrine
Article | Year |
---|---|
The stathmokinetic experiment: a single-parameter and multiparameter flow cytometric analysis.
Topics: Acridine Orange; Amsacrine; Animals; Cell Cycle; Cell Division; DNA; Flow Cytometry; Humans; Mitosis; Vinblastine | 1990 |
Integrated scientific data bases review on asulacrine and associated toxicity.
Topics: Amsacrine; Animals; Antineoplastic Agents; Humans; Neoplasms; Oxidative Stress; Signal Transduction | 2016 |
3 trial(s) available for amsacrine and asulacrine
Article | Year |
---|---|
A phase II trial of CI-921 in advanced malignancies.
Topics: Adult; Aged; Amsacrine; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasms; Treatment Outcome | 1992 |
A phase I trial of amsalog (CI-921) administered by intravenous infusion using a 5-day schedule.
Topics: Adult; Aged; Amsacrine; Antineoplastic Agents; Area Under Curve; Bone Marrow Diseases; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Half-Life; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Topoisomerase II Inhibitors | 2001 |
A study of amsalog (CI-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalation.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Agents; Area Under Curve; Biological Availability; Dose-Response Relationship, Drug; Female; Humans; Injections, Intravenous; Male; Middle Aged; Treatment Outcome | 2002 |
48 other study(ies) available for amsacrine and asulacrine
Article | Year |
---|---|
Potential antitumor agents. 48. 3'-Dimethylamino derivatives of amsacrine: redox chemistry and in vivo solid tumor activity.
Topics: Amsacrine; Animals; Antineoplastic Agents; Carcinoma; Cell Line; Chemical Phenomena; Chemistry; Colonic Neoplasms; DNA; Humans; Leukemia, Experimental; Lung Neoplasms; Mice; Oxidation-Reduction; Structure-Activity Relationship | 1987 |
Potential antitumor agents. 47. 3'-Methylamino analogues of amsacrine with in vivo solid tumor activity.
Topics: Acridines; Aminoacridines; Amsacrine; Animals; Cell Line; Chemical Phenomena; Chemistry; Colonic Neoplasms; DNA; Humans; Leukemia L1210; Leukemia P388; Mice; Solubility; Structure-Activity Relationship | 1986 |
Potential antitumor agents. 40. Orally active 4,5-disubstituted derivatives of amsacrine.
Topics: Administration, Oral; Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; DNA; Female; Injections, Intraperitoneal; Leukemia L1210; Leukemia P388; Male; Mice; Mice, Inbred DBA | 1984 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Novel 4-quinoline-thiosemicarbazone derivatives: Synthesis, antiproliferative activity, in vitro and in silico biomacromolecule interaction studies and topoisomerase inhibition.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Macromolecular Substances; Macrophages; MCF-7 Cells; Mice; Models, Molecular; Molecular Structure; Quinolines; RAW 264.7 Cells; Structure-Activity Relationship; Thiosemicarbazones; Topoisomerase II Inhibitors; Viscosity | 2019 |
Oxidative metabolism of amsacrine by the neutrophil enzyme myeloperoxidase.
Topics: Amsacrine; Humans; Hypochlorous Acid; Leukemia, Myeloid; Neutrophils; Oxidation-Reduction; Peroxidase; Tumor Cells, Cultured | 1992 |
Differences in the metabolism of the antitumour agents amsacrine and its derivative CI-921 in rat and mouse.
Topics: Amsacrine; Animals; Antineoplastic Agents; Bile; Chromatography, High Pressure Liquid; Kinetics; Mice; Rats | 1992 |
Comparison of the blood-brain barrier and liver penetration of acridine antitumor drugs.
Topics: Acridines; Aminoacridines; Amsacrine; Anesthesia; Animals; Antineoplastic Agents; Barbiturates; Blood-Brain Barrier; Brain; Butanols; Carotid Arteries; Diazepam; Injections, Intra-Arterial; Injections, Intravenous; Liver; Mice; Portal Vein | 1992 |
Developmental toxicity of CI-921, an anilinoacridine antitumor agent.
Topics: Abnormalities, Drug-Induced; Amsacrine; Animals; Antineoplastic Agents; Embryo Implantation; Female; Fetal Death; Intercalating Agents; Male; Pregnancy; Rabbits; Rats; Rats, Inbred Strains; Sex Ratio | 1992 |
Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.
Topics: Adult; Aged; Amsacrine; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Evaluation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Seizures | 1991 |
Potentiation by phenylbisbenzimidazoles of cytotoxicity of anticancer drugs directed against topoisomerase II.
Topics: Acridines; Amsacrine; Animals; Antineoplastic Agents; Benzimidazoles; Bisbenzimidazole; Colonic Neoplasms; Doxorubicin; Drug Synergism; Etoposide; Fluorescent Dyes; Leukemia L1210; Lung Neoplasms; Melanoma; Mice; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1990 |
Comparison of the cytotoxicity of amsacrine and its analogue CI-921 against cultured human and mouse bone marrow tumour cells.
Topics: Amsacrine; Animals; Antineoplastic Agents; Bone Marrow; Cell Survival; Humans; Leukemia L1210; Leukemia, Experimental; Mice; Tumor Cells, Cultured | 1990 |
Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice.
Topics: Amsacrine; Animals; Antineoplastic Agents; Carcinoma; Liver; Lung Neoplasms; Male; Metabolic Clearance Rate; Mice; Solubility | 1990 |
Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs, and humans.
Topics: Amsacrine; Animals; Antineoplastic Agents; Dogs; Half-Life; Humans; Metabolic Clearance Rate; Mice; Rabbits; Rats; Species Specificity | 1990 |
Effects of a new amsacrine derivative, N-5-dimethyl-9-(2-methoxy-4-methylsulfonylamino)phenylamino-4- acridinecarboxamide, on cultured mammalian cells.
Topics: Amsacrine; Animals; Cell Cycle; Cell Survival; Cells, Cultured; Chromatin; Cricetinae; DNA; Drug Administration Schedule; Intercalating Agents; Interphase; Mice; Mitosis; Nucleic Acid Denaturation; Proteins; RNA; Vinblastine | 1987 |
Chemoprotection by 9-aminoacridine derivatives against the cytotoxicity of topoisomerase II-directed drugs.
Topics: Aminacrine; Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Colony-Forming Units Assay; Intercalating Agents; Isomerism; Leukemia P388; Mice; Quinacrine; Topoisomerase II Inhibitors; Tumor Stem Cell Assay | 1989 |
Selectivity of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide towards Lewis lung carcinoma and human tumour cell lines in vitro.
Topics: Acridines; Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Humans; Lung Neoplasms; Mice; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1989 |
The effect of cimetidine, phenobarbitone and buthionine sulphoximine on the disposition of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulphonylamino)phenylamino]- 4-acridinecarboxamide (CI-921) in the rabbit.
Topics: Amsacrine; Animals; Antimetabolites; Antineoplastic Agents; Buthionine Sulfoximine; Cimetidine; Dose-Response Relationship, Drug; Drug Interactions; Female; Glutathione; Male; Methionine Sulfoximine; Phenobarbital; Rabbits; Time Factors | 1989 |
Evaluation of an amsacrine analog in a human tumor cloning system.
Topics: Amsacrine; Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Drug Resistance; Humans; Lung Neoplasms; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1989 |
Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II.
Topics: Acridines; Aminacrine; Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Cell Survival; DNA Damage; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Leukemia L1210; Leukemia P388; Leukemia, Experimental; Mice; Neoplasm Proteins; Quinacrine; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1988 |
The effect of food on the bioavailability and kinetics of the anticancer drug amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino)phenylamino]-4 acridinecarboxamide in rabbits.
Topics: Amsacrine; Animals; Antineoplastic Agents; Biological Availability; Food; Kinetics; Rabbits | 1986 |
Phase I trial of the amsacrine analogue 9-[( 2-methoxy-4-[(methylsulfonyl)amino]-phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921).
Topics: Adult; Aged; Amsacrine; Antineoplastic Agents; Drug Evaluation; Female; Humans; Male; Middle Aged; Neoplasms | 1988 |
Thiolytic cleavage and binding of the antitumour agent CI-921 in blood.
Topics: Acetonitriles; Amsacrine; Animals; Antineoplastic Agents; Blood Proteins; Chromatography, High Pressure Liquid; In Vitro Techniques; Male; Mice; Mice, Inbred Strains; Sulfur | 1988 |
Involvement of glutathione in the metabolism of the anilinoacridine antitumour agents CI-921 and amsacrine.
Topics: Amsacrine; Animals; Antineoplastic Agents; Bile; Biotransformation; Chromatography, High Pressure Liquid; Cytosol; Feces; Glutathione; In Vitro Techniques; Male; Mice; Mice, Inbred Strains; Microsomes, Liver; Spectrophotometry, Ultraviolet | 1988 |
Comparison of the mutagenicity of amsacrine with that of a new clinical analogue, CI-921.
Topics: Amsacrine; Animals; Cell Line; Cell Nucleus; Cell Transformation, Neoplastic; Chromosome Aberrations; Cricetinae; Cricetulus; Fibroblasts; Lung; Male; Mice; Mice, Inbred C3H; Microsomes, Liver; Mutagenicity Tests; Rats; Rats, Inbred Strains; Salmonella typhimurium | 1988 |
Effects of CI-921, an analogue of amsacrine, on advanced Lewis lung tumours in mice: relevance to clinical trials.
Topics: Amsacrine; Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Flow Cytometry; Lung; Lung Neoplasms; Mice; Time Factors; Tumor Cells, Cultured | 1988 |
The clinical pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulfonylamino)phenylamino]-4 -acridinecarboxamide (CI-921) in a phase 1 trial.
Topics: Adult; Aged; Amsacrine; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Infusions, Intravenous; Male; Middle Aged | 1988 |
Cytokinetic factors in drug resistance of Lewis lung carcinoma: comparison of cells freshly isolated from tumours with cells from exponential and plateau-phase cultures.
Topics: Amsacrine; Animals; Antineoplastic Agents; Cell Survival; Doxorubicin; Drug Resistance; Interphase; Lung Neoplasms; Mice; Mice, Inbred Strains; Mitosis; Time Factors; Tumor Cells, Cultured | 1987 |
Experimental antitumor activity of the amsacrine analogue CI-921.
Topics: Amsacrine; Animals; Antineoplastic Agents; Cell Line; Colonic Neoplasms; Disease Models, Animal; Drug Evaluation, Preclinical; Lung Neoplasms; Mammary Neoplasms, Experimental; Mice; Mice, Inbred Strains | 1987 |
Dose-dependent pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino)phenylamino]- 4-acridinecarboxamide (CI-921) in rabbits.
Topics: Amsacrine; Animals; Chromatography, High Pressure Liquid; Infusions, Intravenous; Kinetics; Rabbits | 1987 |
Comparison of in vivo and in vitro drug sensitivities of Lewis lung carcinoma and P388 leukaemia to analogues of amsacrine.
Topics: Amsacrine; Animals; Antineoplastic Agents; Cell Line; Drug Evaluation, Preclinical; Female; Leukemia P388; Leukemia, Experimental; Lung Neoplasms; Mice; Neoplasm Transplantation; Tumor Stem Cell Assay | 1987 |
Comparison of the pharmacokinetics and protein binding of the anticancer drug, amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenyl-amino] -4-acridinecarboxamide in rabbits.
Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Blood Proteins; Half-Life; Kinetics; Metabolic Clearance Rate; Protein Binding; Rabbits | 1986 |
CI-921: an analog of amsacrine with experimental activity against solid tumors.
Topics: Aminoacridines; Amsacrine; Animals; Cell Cycle; Cells, Cultured; Metabolic Clearance Rate; Mice; Neoplasms, Experimental; Solubility | 1986 |
Effects of anthrapyrazole antineoplastic agents on lipid peroxidation.
Topics: Amsacrine; Animals; Anthraquinones; Antineoplastic Agents; Doxorubicin; In Vitro Techniques; Iron; Lipid Peroxides; Male; Microsomes, Liver; Pyrazoles; Pyrazolones; Rabbits | 1986 |
Cytokinetic resistance of Lewis lung carcinoma to cyclophosphamide and the amsacrine derivative CI-921.
Topics: Amsacrine; Animals; Antineoplastic Agents; Cell Cycle; Cell Line; Cyclophosphamide; Drug Resistance; Lung Neoplasms; Mice; Neoplasms, Experimental; Tumor Stem Cell Assay | 1986 |
Determination of N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenylamino]-4 -acridinecarboxamide in plasma by high-performance liquid chromatography.
Topics: Aminoacridines; Amsacrine; Antineoplastic Agents; Chromatography, High Pressure Liquid; Humans; Kinetics | 1985 |
Schedule dependence of activity of the amsacrine analogue CI-921 towards P388 leukaemia and Lewis lung carcinoma.
Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Injections, Intraperitoneal; Leukemia P388; Leukemia, Experimental; Lung Neoplasms; Male; Mice; Mice, Inbred Strains | 1985 |
Synthesis, antitumor activity, and DNA binding properties of a new derivative of amsacrine, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino) phenylamino]-4-acridinecarboxamide.
Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Cattle; Cell Division; Cell Line; Cell Survival; Cricetinae; DNA; Drug Evaluation, Preclinical; Humans; Indicators and Reagents; Intercalating Agents; Leukemia L1210; Leukemia P388; Lung Neoplasms; Mice; Mice, Inbred Strains; Thymus Gland | 1984 |
Development and validation of bioanalytical method for the determination of asulacrine in plasma by liquid chromatography.
Topics: Amsacrine; Animals; Antineoplastic Agents; Chromatography, Liquid; Mice; Quality Control; Reference Standards; Reproducibility of Results; Spectrophotometry, Ultraviolet | 2008 |
Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery.
Topics: Amsacrine; Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Crystallization; Drug Compounding; Drug Stability; Drug Storage; Injections, Intravenous; Male; Mice; Mice, Inbred C57BL; Microscopy, Electron, Scanning; Nanoparticles; Particle Size; Solubility; Surface Properties; Suspensions; Tissue Distribution | 2009 |
Physicochemical characterization of asulacrine towards the development of an anticancer liposomal formulation via active drug loading: stability, solubility, lipophilicity and ionization.
Topics: Amsacrine; Antineoplastic Agents; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Drug Stability; Hydrogen-Ion Concentration; Liposomes; Solubility | 2014 |
Strategies to maximize liposomal drug loading for a poorly water-soluble anticancer drug.
Topics: Ammonium Sulfate; Amsacrine; Animals; Antineoplastic Agents; beta-Cyclodextrins; Drug Carriers; Infusions, Intravenous; Liposomes; Molecular Structure; Rabbits; Solubility; Technology, Pharmaceutical | 2015 |
Post-insertion of poloxamer 188 strengthened liposomal membrane and reduced drug irritancy and in vivo precipitation, superior to PEGylation.
Topics: Amsacrine; Animals; Antineoplastic Agents; Chemical Precipitation; Infusion Pumps; Injections; Liposomes; Male; Phlebitis; Poloxamer; Polyethylene Glycols; Rabbits; Rats, Sprague-Dawley | 2015 |
Improving drug retention in liposomes by aging with the aid of glucose.
Topics: Amsacrine; Animals; Antineoplastic Agents; Calorimetry, Differential Scanning; Chemical Precipitation; Chemistry, Pharmaceutical; Drug Liberation; Glucose; Half-Life; Infusions, Intravenous; Liposomes; Microscopy, Electron, Transmission; Phase Transition; Rabbits; Solubility | 2016 |
Identification and characterization of in vivo metabolites of asulacrine using advanced mass spectrophotometry technique in combination with improved data mining strategy.
Topics: Amsacrine; Animals; Bile; Data Mining; Female; Male; Mass Spectrometry; Molecular Weight; Rats; Software; Urine | 2016 |
Quantitative determination of intracellular Asulacrine in MCF-7 breast cancer cells by liquid chromatography-mass spectrometry and its application to cellular pharmacokinetic studies of P188 modified liposomes.
Topics: Amsacrine; Antineoplastic Agents; Breast Neoplasms; Chromatography, Liquid; Female; Humans; Liposomes; Mass Spectrometry; MCF-7 Cells; Reproducibility of Results | 2016 |
Optimization of Weight Ratio for DSPE-PEG/TPGS Hybrid Micelles to Improve Drug Retention and Tumor Penetration.
Topics: Amsacrine; Animals; Antineoplastic Agents; Cell Culture Techniques; Cell Survival; Delayed-Action Preparations; Drug Carriers; Drug Liberation; Drug Stability; Half-Life; Humans; Male; MCF-7 Cells; Micelles; Nanoparticles; Particle Size; Permeability; Phosphatidylethanolamines; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Surface Properties; Vitamin E | 2018 |
Multiseed liposomal drug delivery system using micelle gradient as driving force to improve amphiphilic drug retention and its anti-tumor efficacy.
Topics: Amsacrine; Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Delivery Systems; Female; Liposomes; Male; Mice; Mice, Inbred BALB C; Micelles; Rats; Rats, Sprague-Dawley; Surface-Active Agents; Treatment Outcome; Tumor Burden | 2018 |